Nasdaq: SCTX · Listed Jul 24, 2026
Scribe Therapeutics IPO
IPO price
$15.00
Scribe Therapeutics (SCTX) priced its IPO at $15.00 a share and has traded on Nasdaq since Jul 24, 2026.
SCTX today$14.25-5.00%since IPO15-min delayed · as of 4:24:20 AM EST on Nov 19, 2026
See the SCTX quoteFirst trading day · Jul 24, 2026
- IPO price
- $15.00
- the top of the range of $13 to $15
- First trade
- $25.00
- +66.67% from the IPO price
- First-day last trade
- $22.00
- +46.67% from the IPO price, regular session
- Raise
- $128.7M
- before the underwriters' option
These numbers are from the first trading day, Jul 24, 2026.
How SCTX did against the market
SCTX against the market, from its first trade at 11:45 ET to the last trade of the session.
- SCTX from its first trade
- -12.00%
- Against the market (QQQ)
- -11.2 pts
SCTX fell 12.0% from its first trade to the last trade of the session. That is 11.2 points worse than the market.
Same-day moves do not show that SCTX caused them. The market is QQQ, the Nasdaq-100 ETF.
The debut race
SCTX against other big listings, as the percent change from each stock's own IPO price.
The first 30 trading days. Each point is the last regular-session trade of a day.
The first trading day.
The first trading day.
The IPO scoreboard
SCTX against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.
| IPO | Raised | First trade | Day 1 close | Day 1 close, as a bar | Day 5 | Day 30 |
|---|---|---|---|---|---|---|
| Scribe Therapeutics '26 | $128.7M | +66.67% | +46.67% | +36.00% | +104.80% | |
| Figma '25 | $1.22B | +157.58% | +252.42% | +173.64% | +69.64% | |
| Circle '25 | $1.05B | +122.58% | +168.45% | +278.18% | +622.98% | |
| Reddit '24 | $748M | +38.24% | +47.97% | +69.90% | +40.32% | |
| Arm '23 | $5.23B | +10.00% | +23.76% | +3.63% | -3.06% | |
| Klarna '25 | $1.37B | +30.00% | +16.14% | +13.73% | -7.33% | |
| CoreWeave '25 | $1.5B | -2.50% | +0.02% | +34.32% | +28.42% |
Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.
The offering
The Scribe Therapeutics IPO offers 8.58M shares to raise $128.7M, before any underwriters' option.
- Expected price range
- $13 to $15
- IPO price
- $15.00
- Shares offered
- 8.58M
- Money raised
- $128.7M
- Listing date
- Jul 24, 2026
- Exchange
- Nasdaq
- Security
- Ordinary Shares
Money raised, against the largest IPOs
- Alibaba '14$21.77B
- Facebook '12$18.41B
- Rivian '21$11.93B
- Uber '19$8.1B
- Arm '23$5.23B
- Scribe Therapeutics$128.7M
Where SCTX ranks
Scribe Therapeutics's market cap against the largest US-listed companies.
Market cap, against the largest US-listed companies
- AAPL$5.12T
- MSFT$3.77T
- NVDA$3.65T
- GOOGL$3.47T
- AMZN$2.9T
- TSM$1.88T
- AVGO$1.69T
- META$1.58T
- TSLA$1.52T
- BRK.B$1.22T
- SCTX$266.07M
SCTX news
The latest news and headlines about Scribe Therapeutics (SCTX).
- Cathie Wood Bought Just 3 Stocks On Monday; Here They AreneutralThe Motley Fool· Nov 10, 2026
Filings and the company
What Scribe Therapeutics has disclosed to the SEC, and the basic facts about the listing.
8-K filings
Material events that Scribe Therapeutics discloses to the SEC on Form 8-K.
- Quarterly earningsNov 12, 2026
On November 12, 2026, Scribe Therapeutics Inc. (the "Company") announced its financial results for the quarter ended September 30, 2026 and provided a business update.
- Quarterly earningsSep 2, 2026
On September 2, 2026, Scribe Therapeutics Inc. (the "Company") announced its financial results for the quarter ended June 30, 2026 and provided a business update.
- Charter amendmentJul 27, 2026
On July 27, 2026, Scribe Therapeutics Inc. (the "Company") filed its Amended and Restated Certificate of Incorporation (the "Charter") with the Secretary of State of the State of Delaware... in connection with the closing of the initial public offering (the "Offering") of shares of the Company's common stock.
About Scribe Therapeutics
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
- Ticker
- SCTX
- Exchange
- Nasdaq
- Market
- stocks
- Type
- CS
- Currency
- USD
- Industry
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- Listed
- Jul 24, 2026
- Security
- Ordinary Shares
Frequently asked questions
What was the Scribe Therapeutics IPO price?
$15.00 a share.
When did Scribe Therapeutics go public?
Scribe Therapeutics listed on Nasdaq on Jul 24, 2026 under the ticker SCTX.
How much did the Scribe Therapeutics IPO raise?
$128.7M, before any underwriters' option.
How did Scribe Therapeutics open on its first day?
SCTX first traded at $25.00, +66.67% from the IPO price of $15.00.
How did SCTX close on its first day?
Its last regular-session trade was $22.00, +46.67% from the IPO price of $15.00.
What was the SCTX first-day trading range?
$21.00 to $25.49 in the regular session.
How many SCTX shares traded on the first day?
924.76K shares in the regular session.
How many shares did Scribe Therapeutics sell in its IPO?
8.58M shares.
How did SCTX do against the market on its first day?
SCTX fell 12.0% from its first trade to the last trade of the session. That is 11.2 points worse than the market (QQQ, the Nasdaq-100 ETF).
What exchange is SCTX listed on?
Scribe Therapeutics lists on Nasdaq under the ticker SCTX.
Build with Massive
Get the SCTX data behind this page
| What the page shows | Endpoint |
|---|---|
| Offering terms and dates | /vX/reference/ipos |
| Price | /v3/snapshot |
| Chart, VWAP, and the market comparison | /v2/aggs/ticker/SCTX/range/5/minute |
| Market cap | /v3/reference/tickers/SCTX |
| News | /v2/reference/news |
| Filings | /vX/disclosures |
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.